Literature DB >> 22929974

Recent trends in survival of adult patients with acute leukemia: overall improvements, but persistent and partly increasing disparity in survival of patients from minority groups.

Dianne Pulte1, Maria Theresa Redaniel, Lina Jansen, Hermann Brenner, Mona Jeffreys.   

Abstract

The survival of younger patients with acute leukemia has improved in the early 21(st) century, but it is unknown whether people of all ethnic and racial backgrounds have benefited equally. Using cancer registry data from the Surveillance, Epidemiology and End Results Program, we assessed trends in 5-year relative survival for patients aged 15 years or more with acute lymphoblastic leukemia and acute myeloblastic leukemia divided by racial and ethnic group, including non-Hispanic whites, African-Americans, Hispanics, and Asian-Pacific Islanders in the 1990s and the early 21(st) century. Modeled period analysis was used to obtain the most up-to-date estimates of survival. Overall, the 5-year survival increased from 31.6% in 1997-2002 to 39.0% in 2003-2008 for patients with acute lymphoblastic leukemia and from 15.5% in 1991-1996 to 22.5% in 2003-2008 for those with acute myeloblastic leukemia. Nevertheless, among patients with acute lymphoblastic leukemia, age-adjusted 5-year relative survival rates remained lower for African-Americans and Hispanics than for non-Hispanic whites. Among patients with acute myeloblastic leukemia, the increase in survival was greatest (from 32.6% in 1991-1996 to 47.1% in 2003-2008) for younger patients (15-54 years), and was more pronounced for non-Hispanic whites (+16.4% units) than for other patients (+10.8% units). Increases in survival are observed in all ethnic or racial groups. Nevertheless, among patients with acute leukemias, disparities in survival persist between non-Hispanic white people and people of other ethnic or racial groups. Disparities are increasing in younger patients with acute myeloblastic leukemia. Improvements in access to treatment, especially for minority patients, may improve outcomes.

Entities:  

Mesh:

Year:  2012        PMID: 22929974      PMCID: PMC3561429          DOI: 10.3324/haematol.2012.063602

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  40 in total

1.  Should HLA-identical sibling bone marrow transplants for leukemia be restricted to large centers?

Authors:  M M Horowitz; D Przepiorka; R E Champlin; R P Gale; A Gratwohl; R H Herzig; H G Prentice; A A Rimm; O Ringdén; M M Bortin
Journal:  Blood       Date:  1992-05-15       Impact factor: 22.113

2.  United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia.

Authors:  S L Soignet; S R Frankel; D Douer; M S Tallman; H Kantarjian; E Calleja; R M Stone; M Kalaycio; D A Scheinberg; P Steinherz; E L Sievers; S Coutré; S Dahlberg; R Ellison; R P Warrell
Journal:  J Clin Oncol       Date:  2001-09-15       Impact factor: 44.544

Review 3.  Acute myeloid leukemia.

Authors:  Jeffrey E Rubnitz; Brenda Gibson; Franklin O Smith
Journal:  Hematol Oncol Clin North Am       Date:  2010-02       Impact factor: 3.722

4.  A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARalpha-positive acute promyelocytic leukemia. PETHEMA group.

Authors:  M A Sanz; G Martín; C Rayón; J Esteve; M González; J Díaz-Mediavilla; P Bolufer; E Barragán; M J Terol; J D González; D Colomer; C Chillón; C Rivas; T Gómez; J M Ribera; R Bornstein; J Román; M J Calasanz; J Arias; C Alvarez; F Ramos; G Debén
Journal:  Blood       Date:  1999-11-01       Impact factor: 22.113

5.  Improving relative survival, but large remaining differences in survival for non-Hodgkin's lymphoma across Europe and the United States from 1990 to 2004.

Authors:  Saskia A M van de Schans; Adam Gondos; Dick Johan van Spronsen; Jadwiga Rachtan; Bernd Holleczek; Roberto Zanetti; Jan Willem W Coebergh; Maryska L G Janssen-Heijnen; Hermann Brenner
Journal:  J Clin Oncol       Date:  2010-11-29       Impact factor: 44.544

6.  Differences in prognostic factors and outcomes in African Americans and whites with acute myeloid leukemia.

Authors:  Mikkael A Sekeres; Bercedis Peterson; Richard K Dodge; Robert J Mayer; Joseph O Moore; Edward J Lee; Jonathan Kolitz; Maria R Baer; Charles A Schiffer; Andrew J Carroll; James W Vardiman; Frederick R Davey; Clara D Bloomfield; Richard A Larson; Richard M Stone
Journal:  Blood       Date:  2004-02-19       Impact factor: 22.113

Review 7.  Acute lymphoblastic leukaemia.

Authors:  Ching-Hon Pui; Leslie L Robison; A Thomas Look
Journal:  Lancet       Date:  2008-03-22       Impact factor: 79.321

8.  Trends in 5- and 10-year survival after diagnosis with childhood hematologic malignancies in the United States, 1990-2004.

Authors:  Dianne Pulte; Adam Gondos; Hermann Brenner
Journal:  J Natl Cancer Inst       Date:  2008-09-09       Impact factor: 13.506

9.  Improvement in survival in younger patients with acute lymphoblastic leukemia from the 1980s to the early 21st century.

Authors:  Dianne Pulte; Adam Gondos; Hermann Brenner
Journal:  Blood       Date:  2008-10-30       Impact factor: 22.113

10.  Adult acute leukaemia.

Authors:  K Atkinson; D G Wells; H M Clink; H E Kay; R Powles; T J McElwain
Journal:  Br J Cancer       Date:  1974-09       Impact factor: 7.640

View more
  40 in total

1.  Myelopathy following intrathecal chemotherapy in adults: a single institution experience.

Authors:  David Cachia; Carlos Kamiya-Matsuoka; Chelsea C Pinnix; Linda Chi; Hagop M Kantarjian; Jorge E Cortes; Naval Daver; Karin Woodman
Journal:  J Neurooncol       Date:  2015-02-10       Impact factor: 4.130

2.  Symptom Management and Psychosocial Needs of Adults With Acute Myeloid Leukemia During Induction Treatment: A Pilot Study.

Authors:  Tara A Albrecht; Michael Boyiadzis; R K Elswick; Angela Starkweather; Margaret Rosenzweig
Journal:  Cancer Nurs       Date:  2017 Nov/Dec       Impact factor: 2.592

3.  Survival of patients with lymphoplasmacytic lymphoma and solitary plasmacytoma in Germany and the United States of America in the early 21st century.

Authors:  Janick Weberpals; Dianne Pulte; Lina Jansen; Sabine Luttmann; Bernd Holleczek; Alice Nennecke; Meike Ressing; Alexander Katalinic; Maximilian Merz; Hermann Brenner
Journal:  Haematologica       Date:  2017-03-09       Impact factor: 9.941

Review 4.  CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia.

Authors:  Shannon L Maude; David T Teachey; David L Porter; Stephan A Grupp
Journal:  Blood       Date:  2015-05-21       Impact factor: 22.113

Review 5.  Racial and ethnic disparities in hematologic malignancies.

Authors:  Kedar Kirtane; Stephanie J Lee
Journal:  Blood       Date:  2017-07-19       Impact factor: 22.113

6.  Low CLL-1 Expression Is a Novel Adverse Predictor in 123 Patients with De Novo CD34+ Acute Myeloid Leukemia.

Authors:  Yan-Yu Wang; Wen-Lian Chen; Xiang-Qin Weng; Yan Sheng; Jing Wu; Jie Hao; Zhan-Yun Liu; Yong-Mei Zhu; Bing Chen; Shu-Min Xiong; Yu Chen; Qiu-Sheng Chen; Hui-Ping Sun; Jun-Min Li; Jin Wang
Journal:  Stem Cells Dev       Date:  2017-09-21       Impact factor: 3.272

Review 7.  Blinatumomab for the treatment of acute lymphoblastic leukemia.

Authors:  Jason B Kaplan; Marina Grischenko; Francis J Giles
Journal:  Invest New Drugs       Date:  2015-09-17       Impact factor: 3.850

8.  Improved survival in adult patients with acute lymphoblastic leukemia in the Netherlands: a population-based study on treatment, trial participation and survival.

Authors:  A G Dinmohamed; A Szabó; M van der Mark; O Visser; P Sonneveld; J J Cornelissen; M Jongen-Lavrencic; A W Rijneveld
Journal:  Leukemia       Date:  2015-08-19       Impact factor: 11.528

9.  Delays in postremission chemotherapy for Philadelphia chromosome negative acute lymphoblastic leukemia are associated with inferior outcomes in patients who undergo allogeneic transplant: An analysis from ECOG 2993/MRC UK ALLXII.

Authors:  Anita J Kumar; Phyllis A Gimotty; Joel M Gelfand; Georgina Buck; Jacob M Rowe; Anthony H Goldstone; Adele Fielding; David I Marks; Mark Litzow; Elisabeth Paietta; Hillard M Lazarus; Martin S Tallman; Selina M Luger; Alison W Loren
Journal:  Am J Hematol       Date:  2016-08-22       Impact factor: 10.047

Review 10.  Scientific Achievements May Not Reach Everyone: Understanding Disparities in Acute Leukemia.

Authors:  Manali I Patel
Journal:  Curr Hematol Malig Rep       Date:  2016-08       Impact factor: 3.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.